Tanmay Bhat on GLP-1 Drugs Failing Appetite Suppression & Genetic Report

GLP-1 drugs not working for appetite suppression? Comedian and content creator Tanmay Bhat has sparked important conversations by sharing his personal experience with GLP-1 medications. Widely used for type 2 diabetes and weight management, these drugs like semaglutide and tirzepatide didn't deliver the expected appetite reduction for him, leading him to investigate genetic factors.

Tanmay Bhat's Experience with GLP-1 Medications

In a candid post on X (formerly Twitter), Tanmay Bhat revealed that despite trying GLP-1 receptor agonists, he experienced zero appetite suppression. "Anybody here who's fu**in around with GLP1's experienced zero appetite suppression? I have experienced zero appetite suppression," he wrote. He pointed to his genetic report as a potential explanation: "Upon further investigation, my gene report suggested a BDNF gene variant that is prone to weakened satiety signalling. Anybody here an expert on this matter?"

Bhat didn't stop there. He explored solutions, mentioning a proposed combination therapy: "Another proposed solution that I read was combining Tirz with Cagrilinitide. Unable to find a trustworthy source for Cagri. Any leads would be appreciated." He also sought recommendations for reliable peptide sources in India.

"Chill yaar, I've lost over 75 kilos without touching a single GLP1 injection. But I like all new health tech and I am dabbling with GLP1s to see how I feel about it. I workout, I eat well, I have consistent blood works for the last 5 years. I have great guidance, I know what I'm doing. Spare me moral lecture pls."

Responding to critics who suggested sticking to lifestyle changes alone, Bhat defended his approach by highlighting his impressive 75 kg weight loss history without medications. His posts drew varied responses—some shared similar non-responder experiences, while others offered advice.

Understanding GLP-1 Receptor Agonists: How They Work

GLP-1 receptor agonists, including semaglutide (found in Ozempic and Wegovy) and tirzepatide (in Mounjaro and Zepbound), are FDA-approved for regulating blood sugar in type 2 diabetes. They mimic the glucagon-like peptide-1 hormone, which:

• Slows gastric emptying to promote fullness.
• Reduces appetite by signaling the brain's satiety centers.
• Improves insulin secretion and lowers glucagon levels.

These mechanisms make them popular for weight loss, with many users reporting significant reductions in calorie intake. However, as Bhat's story shows, not everyone responds equally.

BDNF Gene Variant and Satiety Signaling

The brain-derived neurotrophic factor (BDNF) gene plays a role in brain health, neuroplasticity, and appetite regulation. Variants in BDNF can impair satiety signaling pathways, potentially explaining why some individuals like Bhat see no appetite changes from GLP-1 drugs. This genetic factor influences how the brain processes fullness signals from the gut, even when medications target GLP-1 receptors.

Why GLP-1 Drugs May Not Suppress Appetite in Some People

Medical experts, including those at the Cleveland Clinic, emphasize that GLP-1 medications' effectiveness varies. Here are key reasons some experience zero appetite suppression:

Dose and Adjustment Period

These drugs start at low doses (e.g., 0.25 mg semaglutide weekly) and titrate up over weeks or months. Full appetite effects may not appear until higher doses, requiring patience. Rushing can lead to side effects without benefits.

Genetic and Biological Differences

"Non-responders" exist due to genetics like BDNF variants, metabolic rates, or hormone imbalances. Conditions such as PCOS, thyroid issues, or insulin resistance can also blunt responses.

Diet and Lifestyle Factors

Diets high in refined carbs and ultra-processed foods may counteract GLP-1 effects. In contrast, protein-rich, fiber-packed meals enhance satiety. Bhat's healthy lifestyle (workouts, consistent bloodwork) underscores that even optimized habits don't guarantee response.

Potential Solutions: Combination Therapies and Next Steps

Bhat mentioned combining tirzepatide (Tirz) with cagrilintide, an amylin analog that enhances satiety via different pathways. This dual approach targets multiple hunger signals, showing promise in trials for better weight loss in partial responders. Always source from trustworthy providers, especially peptides in regions like India.

Other strategies include:

• Switching GLP-1 brands or doses under supervision.
• Adding SGLT2 inhibitors or metformin for synergy.
• Genetic testing for personalized therapy.

Safety Considerations and Side Effects with GLP-1 Drugs

While effective for many, GLP-1s carry risks like nausea, gastrointestinal issues, and rare pancreatitis. Non-responders may still face these without benefits, highlighting the need for monitoring. Tools like Shotlee can help track symptoms, side effects, and medication schedules to inform doctors.

Tanmay Bhat's Weight Loss Journey: A Reminder It's Not One-Size-Fits-All

Bhat's 75 kg loss without drugs proves lifestyle's power, yet his GLP-1 trial reflects curiosity about innovative therapies. Health experts stress: weight management is individualized. GLP-1s work under medical supervision with personalized plans accounting for genetics and habits.

Key Takeaways: What This Means for Patients

• Individual variability is normal: Zero appetite suppression doesn't mean failure—explore genetics like BDNF variants.
• Start slow: Allow time for dose titration.
• Optimize lifestyle: Prioritize whole foods to amplify effects.
• Discuss combos: Ask about tirzepatide + cagrilintide or alternatives.
• Seek supervision: Regular bloodwork and doctor guidance are essential.

Patients considering GLP-1s should consult endocrinologists or metabolic specialists. Genetic reports can guide therapy, preventing frustration like Bhat's.

Conclusion: Navigating GLP-1 Response with Informed Choices

Tanmay Bhat's openness about GLP-1 drugs not working for him—and his BDNF gene insight—reminds us that advanced treatments aren't universal. By understanding mechanisms, genetic influences, and optimization strategies, patients can achieve better outcomes. If you're a non-responder, discuss testing, combos, and tracking apps with your provider for tailored metabolic health success.